Noom BBB and Consumer-Complaint Trends: What the Data Actually Show

Is Noom Legitimate?

Noom is a legally registered company incorporated in New York and operating under U.S. Consumer-protection law. It has processed tens of millions of subscriptions and publishes peer-reviewed outcome data. Legitimate does not mean complaint-free, however. The Better Business Bureau has assigned Noom an F rating, citing failure to resolve a high volume of consumer complaints within the bureau's standard timeframe.

What "Legitimate" Means in This Context

The FTC defines a legitimate subscription service as one that discloses material terms clearly before billing, offers a straightforward cancellation mechanism, and honors stated refund policies under its Negative Option Rule, finalized in 2024 [1]. Noom's subscription structure, a recurring charge that continues until the user actively cancels, falls squarely within the rule's scope.

Noom's app is available on Apple's App Store and Google Play. Its coaching staff holds certifications, though coaches are not licensed clinicians. Its GLP-1 program pairs app-based behavioral coaching with an asynchronous telehealth visit for a prescription. That separation of coaching from prescribing is a common telehealth model, not inherently problematic, but it does create distinct regulatory obligations.

Peer-Reviewed Outcome Data

A randomized controlled trial published in BMJ Open (N=111) found that Noom users lost a mean 1.75 kg more than control participants over 16 weeks [2]. A separate analysis in Scientific Reports (N=35,921 Noom users) reported a mean weight loss of 5.9 kg over the first 6 months for participants who logged meals at least 30 days [3]. These figures are real but modest, and both studies carry industry-adjacent funding disclosures. The CDC's evidence review of digital weight-loss interventions notes that app-based programs generally produce 2 to 5 percent body-weight reductions [4].

Noom's BBB Rating and What Drives It

The Better Business Bureau is not a government regulator, but its complaint database is among the largest publicly searchable records of consumer grievances in the United States. Noom's F rating reflects a pattern the BBB identifies as "failure to respond to complaints" and "unresolved complaints," not fraud conviction.

Volume and Categories of BBB Complaints

As of January 2025, Noom carries more than 1,900 complaints filed in the preceding 36 months on the BBB portal. The breakdown by category runs roughly as follows:

• Billing and collection issues: approximately 55 percent of complaints
• Problems with product or service: approximately 30 percent
• Advertising and sales issues: approximately 10 percent
• Delivery and guarantee issues: the remainder

The most frequent specific grievance is an auto-renewal charge that the consumer states they did not expect or could not cancel through a clearly disclosed process. A secondary cluster involves the 14-day refund guarantee, with users reporting difficulty meeting undisclosed eligibility conditions.

How the BBB F Rating Is Calculated

The BBB scores businesses on a 100-point scale across 13 factors, including complaint volume relative to business size, complaint resolution rate, and time in business [5]. Noom's score falls below the 59-point threshold for an F. The company has been a BBB accredited business in the past but lost accreditation. An F rating does not equal a fraud finding; it means the company has not resolved complaints to the BBB's satisfaction at the rate the bureau expects.

Context: Comparison to Similar Platforms

Weight Watchers (WW) holds a BBB rating of B-minus with roughly 300 complaints over 36 months. Calibrate, a GLP-1 telehealth competitor that ceased operations in 2023, accumulated more than 800 BBB complaints before closure, many citing prescription abandonment after prepayment. Ro Body (Roman Health) holds a BBB rating of B with approximately 150 complaints. Noom's complaint volume is substantially higher in absolute terms than any current direct competitor in the app-based weight-loss category.

FTC Oversight and the Negative Option Rule

The FTC's updated Negative Option Rule, published in the Federal Register on November 15, 2024, makes it a violation of 16 C.F.R. Part 425 to charge a consumer under a recurring billing plan without (a) obtaining express informed consent before the charge, (b) providing a simple cancellation mechanism, and (c) sending an annual reminder for plans lasting more than one year [1].

Why Noom's Model Is Under Scrutiny

Noom sells plans ranging from 4 months to 12 months, billed upfront or monthly. Users who purchase an annual plan and attempt to cancel mid-term report, in BBB filings, being offered credits rather than refunds and being directed to a cancellation flow embedded several screens deep in the app. The FTC has not issued a civil investigative demand against Noom that is publicly disclosed, but the agency's 2023 enforcement action against Amazon's Prime subscription (FTC v. Amazon.com, Inc.) established the template the bureau now applies to any recurring digital subscription [6].

State-Level Attorney General Actions

New York and California attorneys general have consumer-protection statutes that independently govern automatic-renewal subscriptions. California's Automatic Renewal Law (Cal. Bus. & Prof. Code §§ 17600-17606) requires clear disclosure and a cost-effective cancellation method. The California AG's office does not currently list Noom as a named defendant in a public enforcement action, but the California AG's consumer-alert page includes recurring subscription cancellation as an active enforcement priority [7].

Noom's GLP-1 Program: Regulatory and Clinical Considerations

Noom launched its GLP-1 program, branded Noom Med, in 2023. The program offers asynchronous telehealth consultations leading to prescriptions for semaglutide or tirzepatide, including compounded versions during FDA-designated shortage periods.

How the Prescribing Model Works

A user completes an online intake form. A licensed provider reviews the form asynchronously and, if medically appropriate, issues a prescription. The prescription may route to a 503B outsourcing facility for compounded semaglutide. The FDA's list of drug shortages previously included branded semaglutide (Ozempic, Wegovy) during 2022 to 2024, permitting compounding under 21 U.S.C. § 503B [8]. The FDA removed Wegovy from the shortage list in February 2025, which affects the legal status of new compounded semaglutide prescriptions going forward.

Clinical Validity of the Behavioral Plus GLP-1 Combination

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg subcutaneously once weekly produced a mean 14.9 percent body-weight reduction at 68 weeks versus 2.4 percent with placebo (P<0.001) [9]. Combining a GLP-1 receptor agonist with a structured behavioral program may improve outcomes. A 2023 study in Obesity (N=175) found that patients receiving semaglutide alongside a digital coaching program lost 16.2 percent of body weight at 52 weeks versus 12.9 percent with semaglutide alone (P<0.05) [10]. Noom's behavioral component, if adhered to, has a biologically plausible additive effect.

LegitScript Certification and Pharmacy Oversight

LegitScript is the certification body used by Google and Meta to approve telehealth platforms for pharmaceutical advertising. As of January 2025, Noom Med does not appear on LegitScript's list of certified telehealth providers [11]. The absence of certification does not make Noom's prescribing illegal, but it does mean the platform has not submitted to LegitScript's independent audit of prescribing standards, pharmacy sourcing, and provider credentialing. Hims & Hers and LifeMD have both obtained LegitScript certification for their GLP-1 programs.

FDA Warning Letters to Compounding Pharmacies

The FDA has issued warning letters to multiple 503A compounding pharmacies supplying telehealth GLP-1 programs. In April 2024, the agency issued a warning letter to Belmar Pharmacy citing lack of valid prescriptions and inadequate quality controls (FDA Warning Letter April 2024) [12]. Noom has not publicly disclosed which compounding pharmacies fulfill its GLP-1 prescriptions. Consumers considering Noom Med should request the dispensing pharmacy's name and verify its registration with the FDA's drug establishment database [13].

Cancellation and Refund: What Users Should Know Before Enrolling

The table below is an original decision framework compiled by the HealthRX medical and legal-review team from Noom's published terms of service (reviewed January 2025), BBB complaint data, and the FTC's Negative Option Rule.

| Scenario | Noom's Stated Policy | Common Complaint Pattern | |---|---|---| | Cancel within 14 days of purchase | Full refund under "Noom Guarantee" | Eligibility conditions (logging requirements) often not clearly disclosed pre-purchase | | Cancel after 14 days, annual plan | No cash refund; credit offered | Users report being unable to reach cancellation support in time | | Cancel GLP-1 (Noom Med) subscription | Separate cancellation from app subscription required | Users charged for both app and medical program separately | | Auto-renewal 7-day notice | Email notice required per FTC rule | Complaints cite spam folder delivery and insufficient lead time | | Dispute via credit card chargeback | User right under Reg E / Reg Z | Noom reportedly contests chargebacks citing terms-of-service agreement |

Steps to Cancel Noom Safely

1. Log into the Noom app. Manage to Settings, then Account, then "Manage My Plan."
2. Select "Cancel Subscription" and screenshot each confirmation screen.
3. Email support@noom.com with a written cancellation request referencing your account email and the date. Keep the delivery receipt.
4. If auto-renewed after cancellation confirmation, file a dispute with your card issuer under Regulation Z (12 C.F.R. Part 1026) [14] or Regulation E for debit cards [15].
5. File a complaint with the FTC at ReportFraud.ftc.gov and with the BBB if the dispute is not resolved within 30 days.

How to Evaluate Any Telehealth Weight-Loss Program

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should prescribe anti-obesity medications only as an adjunct to intensive lifestyle intervention, not as a standalone therapy" [16]. That standard applies to Noom Med and every competing program. Before enrolling:

Checklist for Evaluating a GLP-1 Telehealth Platform

• Synchronous provider visit: Does the platform offer a live video or phone consultation, or is the intake entirely asynchronous?
• Lab requirements: Does the provider order baseline HbA1c, lipid panel, and thyroid screening before prescribing? The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend baseline metabolic workup [17].
• Pharmacy transparency: Is the dispensing pharmacy's DEA and FDA registration number disclosed?
• Subscription terms: Are the auto-renewal date, cancellation method, and refund conditions presented before the payment screen, not buried in terms of service?
• LegitScript certification: Search legitscript.com for the platform's certification status [11].

A 2022 systematic review in JAMA Internal Medicine covering 23 direct-to-consumer telehealth prescribing audits found that 67 percent of platforms prescribed a controlled substance or high-risk medication without requesting medical records or ordering labs, raising patient-safety concerns [18]. Weight-loss medications fall outside the "controlled substance" category in most cases, but the prescribing-quality concern applies directly.

What Noom Does Well

Criticism of Noom's billing practices should not obscure its clinical contributions. The cognitive behavioral framework Noom uses, drawn from self-determination theory and the Health Belief Model, is evidence-based. A 2016 study in Scientific Reports (N=35,921) confirmed the dose-response relationship between Noom logging frequency and weight loss [3]. The app's food color-coding system (green, yellow, red) maps to caloric density classifications supported by the Dietary Guidelines for Americans 2020-2025 [19].

Noom also publishes outcome data, which many competitors do not. Its coaching model, while not staffed by licensed dietitians in most cases, follows a structured curriculum. The platform's behavioral layer adds something a standalone GLP-1 prescription does not provide.

The gap between Noom's clinical product quality and its billing-practice quality is wide. A user who understands the subscription terms fully, uses the app consistently, and qualifies medically for GLP-1 therapy may achieve clinically meaningful weight loss. A user who enrolls impulsively, finds cancellation difficult, and disputes a charge is far more likely to become one of Noom's 1,900-plus BBB complainants.

Noom vs. Competitors: Complaint Profile Comparison

| Platform | BBB Rating | 36-Month Complaints | LegitScript GLP-1 Certified | Synchronous Provider Visit | |---|---|---|---|---| | Noom | F | 1,900+ | No | No (async only) | | Hims & Hers | B+ | ~150 | Yes | Optional | | Ro Body | B | ~150 | Yes | Optional | | WeightWatchers (WW) | B- | ~300 | N/A (no GLP-1 Rx) | N/A | | Found | B | ~80 | Yes | Yes |

Sources: BBB.org (accessed January 2025), LegitScript.com (accessed January 2025) [5, 11].